Mocetinostat

Drug Profile

Mocetinostat

Alternative Names: MG-0103; MGCD 0103; MGCD103; Mocetinostat dihydrobromide

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator MethylGene
  • Developer MedImmune; MethylGene; Mirati Therapeutics
  • Class Antineoplastics; Benzamides; Pyrimidines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes; Diffuse large B cell lymphoma; Hodgkin's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase Unknown Head and neck cancer
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Acute myeloid leukaemia; Hodgkin's disease

Most Recent Events

  • 13 Dec 2016 University Health Network, Toronto, AstraZeneca and Mirati Therapeutics plan a phase I trial for Head and neck cancer (Combination therapy, Neoadjuvant therapy) in Canada (PO) (NCT02993991)
  • 01 Dec 2016 Investigation in Head and neck cancer in Canada (PO) before December 2016
  • 10 Nov 2016 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT02954991)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top